SBRT2015

Rociletinib in T790 EGFR-mutant NSCLC

Rociletinib is an irreversible, highly selective TKI of mutations of EGFR (activating and T790M)

• 72 patients, median age 59; 14% Asian • Objective response rate in 46 patients with T790M- positive disease was 59% (95% CI 45 to 73) • Median PFS not reached, estimated >12 months

Sequist L, NEJM 201